跳至主要内容
临床试验/EUCTR2019-002880-82-GB
EUCTR2019-002880-82-GB进行中(未招募)1 期

Randomised controlled trial of Gestational treatment with Ursodeoxycholic Acid compared to Metformin to Reduce effects of Diabetes mellitus - GUARD

King's College London0 个研究点目标入组 158 人开始时间: 2020年6月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
158

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1. Women between 16 and 45 years of age with GDM diagnosed at 26+0 to 30+6 weeks’ gestation in accordance with the NICE guidelines (one or more glucose concentrations of =5.6 mmol/l fasting or =7.8 mmol/l 2 hours after a standard 75g OGTT, and requiring pharmacological treatment).
  • 2. Overweight or obese (Booking BMI =25 kg/m2)
  • 3. Planned antenatal, birth intrapartum and postpartum care at the participating centre (i.e. not planning to move before delivery).
  • Eligibility criteria for GUARD MEC is included in the protocol in section 19.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 158
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 158
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1.Unwilling/unable to give written informed consent and comply with the requirements of the study protocol
  • 2.Multiple pregnancies (twins, triplets etc) in current pregnancy
  • 3.Congenital anomaly on ultrasound requiring fetal medicine input
  • 4.Previous diagnosis of diabetes outside pregnancy
  • 5.HbA1c at booking of current pregnancy of >48 mmol/mol or =6.5% (if available)
  • 6.Significant pre-pregnancy comorbidities that increase risk in pregnancy, for example renal failure, severe liver disease, transplantation, cardiac failure, psychiatric conditions requiring in-patient admission (within previous year) in the opinion of the responsible clinician or the CI.
  • 7.Significant co-morbidity in the current pregnancy, nephropathy (estimated GFR <60ml/min), other physical or psychological conditions likely to interfere with the conduct of the study and/or interpretation of the trial results in the opinion of the responsible clinician or the CI.
  • 8.Not fluent in English and absence of interpreter or translation services (ie telephone translation services)
  • 9.Participating in another intervention study where the results could influence GDM-related endpoints, in the opinion of the responsible clinician or the CI, or participation in a CTIMP during current pregnancy.
  • 10.Known allergy/hypersensitivity/intolerance to the active substance or excipients or patients taking any medications which are contraindicated as per IMP SmPC (as per Section 5.7 of the protocol).
  • Eligibility criteria for GUARD MEC is included in the protocol in section 19.

研究者

相似试验